ImmunoGen, Inc.
IMGN · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $4,338 | $4,971 | $994 | $1,256 |
| - Cash | $606 | $572 | $201 | $275 |
| + Debt | $72 | $72 | $14 | $15 |
| Enterprise Value | $3,804 | $4,471 | $807 | $996 |
| Revenue | $113 | $83 | $50 | $41 |
| % Growth | 36.4% | 66.7% | 21.1% | – |
| Gross Profit | $111 | $82 | $49 | $41 |
| % Margin | 98.1% | 98.9% | 98.7% | 99.6% |
| EBITDA | $31 | -$2 | -$38 | -$54 |
| % Margin | 27.4% | -2.2% | -76.1% | -131.4% |
| Net Income | $31 | -$4 | -$41 | -$59 |
| % Margin | 27.1% | -5.1% | -81.3% | -143.3% |
| EPS Diluted | 0.1 | -0.016 | -0.16 | -0.23 |
| % Growth | 721.1% | 89.9% | 30.4% | – |
| Operating Cash Flow | $3 | -$67 | -$74 | -$60 |
| Capital Expenditures | -$1 | -$0 | -$0 | -$0 |
| Free Cash Flow | $1 | -$67 | -$74 | -$60 |